NYSE ARCA | ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index.
The index seeks to track the performance of the common stock ofU. S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| ERAS | Erasca Inc | Healthcare | Biotechnology | 3.44% |
| OLMA | Olema Pharmaceuticals Inc | Healthcare | Biotechnology | 3.40% |
| COGT | Cogent Biosciences Inc | Healthcare | Biotechnology | 2.72% |
| ALPN | Alpine Immune Sciences Inc | Healthcare | Biotechnology | 2.68% |
| LBPH | Longboard Pharmaceuticals Inc | Healthcare | Biotechnology | 2.54% |
| NUVB | Nuvation Bio Inc | Healthcare | Biotechnology | 2.16% |
| NVAX | Novavax Inc | Healthcare | Biotechnology | 2.12% |
| GERN | Geron Corporation | Healthcare | Biotechnology | 1.84% |
| ELVN | Enliven Therapeutics Inc. | Healthcare | Biotechnology | 1.80% |
| 6XC | SOLENO THERAPEUT. DL-001 | Healthcare | Biotechnology | 1.76% |
| MORF | Morphic Holding Inc | Healthcare | Biotechnology | 1.74% |
| BCTG | BCTG Acquisition Corp | Financial Services | Shell Companies | 1.70% |
| ARWR | Arrowhead Pharmaceuticals Inc | Healthcare | Biotechnology | 1.58% |
| DNTH | Dianthus Therapeutics Inc. | Healthcare | Biotechnology | 1.56% |
| ALMS | Alumis Inc | Healthcare | Biotechnology | 1.46% |
| TRML | Tourmaline Bio Inc. | Healthcare | Biotechnology | 1.40% |
| VERV | Verve Therapeutics Inc | Healthcare | Biotechnology | 1.36% |
| CRVS | Corvus Pharmaceuticals Inc | Healthcare | Biotechnology | 1.33% |
| ACLX | Arcellx Inc | Healthcare | Biotechnology | 1.32% |
| RZLT | Rezolute Inc | Healthcare | Biotechnology | 1.31% |